homepage_v3

Accelerating the Path to a Healthier World

drug_safety_v3

Bringing together pharmaceutical companies to share & validate safety testing methods

Explore our programs to learn more:

alzheimers_v3

Creating and testing Alzheimer’s disease tools to facilitate drug development

Explore our programs to learn more:

tb_v3

Accelerating the development of new, safe, & highly effective tuberculosis treatment regimens

Explore our programs to learn more:

ms3

Developing standards for assessing outcomes in clinical trials of MS therapies

Explore our programs to learn more:

asthma_v3

Collaborating to develop instruments that measure the patient’s perspective

Explore our programs to learn more:

parkinsons_v3

Identifying patients with Parkinson’s disease before symptoms are apparent

Explore our programs to learn more:

pkd_v3

Promoting research to discover treatments that improve the lives of PKD patients

Explore our programs to learn more:

ibs_v3

Working with the FDA and medical product firms to assess patient outcomes

Explore our programs to learn more:

depression

Developing and qualifying PRO instruments with the FDA for use in clinical trials

Explore our programs to learn more:

functional-dyspepsia

Bringing together experts with a range of skills to explore how patients view their therapy

Explore our programs to learn more:

lung_cancer_v3

Qualifying instruments for use in clinical trials to evaluate treatment benefit

Explore our programs to learn more:

ra

Enriching our understanding of the effect of interventions on how patients feel and function

Explore our programs to learn more:

Creating

Consensus Science

C-Path orchestrates the sharing of data, expertise and knowledge among industry, regulatory authorities, government, patient advocacy groups and academia in the pre-competitive space to generate the evidence needed to improve the drug development pathway.

Read More

Defining

Paths

C-Path’s consensus science improves medical product development efficiencies by identifying pathways that integrate new scientific advances into the regulatory review process.


Read More

Improving

Global Health

The failure rate of testing new drug therapies is an astounding (and unacceptable) 95 %. Even worse, many of the failures occur during late-phase testing – after the bulk of research dollars have already been committed.

Read More

drug development timeline
accelerated timeline
Industry
Academia
Regulatory
Agencies

“C-Path has created neutral ground that allows FDA scientists to work collaboratively with industry and academic partners on improving the process.”

Janet Woodcock, MD, FDA